2021
Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent
Yang ES, Nassar AH, Adib E, Jegede OA, Alaiwi SA, Manna DLD, Braun DA, Zarei M, Du H, Pal SK, Naik G, Sonpavde GP. Gene Expression Signature Correlates with Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Everolimus Alone or with a Vascular Disrupting Agent. Molecular Cancer Therapeutics 2021, 20: 1454-1461. PMID: 34108261, DOI: 10.1158/1535-7163.mct-20-1091.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBenzofuransBiomarkers, TumorCarcinoma, Renal CellClinical Trials, Phase III as TopicEverolimusFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansKidney NeoplasmsMaleMiddle AgedOrganophosphatesPrognosisSurvival RateTranscriptomeValidation Studies as TopicConceptsMetastatic renal cell carcinomaMedian PFSClinical benefitDiscovery cohortMetastatic renal cell carcinoma patientsPhase I/II trialRenal cell carcinoma patientsPhase III trialsCell carcinoma patientsLonger median PFSRenal cell carcinomaFour-gene signaturePropensity score covariate adjustmentVascular Disrupting AgentsCheckMate 025Monotherapy useStable diseaseII trialGene expression signaturesIII trialsAppropriate patientsCarcinoma patientsImmune checkpointsCell carcinomaVEGF inhibitors
2019
PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN
Flaifel A, Xie W, Braun DA, Ficial M, Bakouny Z, Nassar AH, Jennings RB, Escudier B, George DJ, Motzer RJ, Morris MJ, Powles T, Wang E, Huang Y, Freeman GJ, Choueiri TK, Signoretti S. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clinical Cancer Research 2019, 25: 6080-6088. PMID: 31371341, PMCID: PMC6801080, DOI: 10.1158/1078-0432.ccr-19-1135.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnilidesB7-H1 AntigenBiomarkers, TumorBiopsyCarcinoma, Renal CellChemotherapy, AdjuvantClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicEverolimusFemaleHumansKaplan-Meier EstimateKidneyKidney NeoplasmsMulticenter Studies as TopicNephrectomyPrognosisProgression-Free SurvivalProtein Kinase InhibitorsPyridinesRandomized Controlled Trials as TopicSunitinibConceptsMetastatic renal cell carcinomaPD-L1 expressionProgression-free survivalOverall survivalRenal cell carcinomaPD-L1Clinical outcomesCell carcinomaPredictive biomarkersClinical trialsTumor cell PD-L1 expressionHigh PD-L1 expressionTC PD-L1 expressionImproved progression-free survivalTumor tissuePoor progression-free survivalIHC double stainingMET expression levelsImmune cell infiltratesPD-L1 statusWorse clinical outcomesPotential predictive biomarkersImmune cell densityIndependent central reviewCABOSUN trial